In Brief | Ophthalmology
 

Melatonin may reduce the risk of age-related Macular Degeneration

 

Time to read: 01:18
 

Published on MedED: 3 July 2024
Originally Published: 6 June 2024
Sourced: JAMA Ophthalmology

Type of article: In Brief
MedED Catalogue Reference: MP0B010

Category: Ophthalmology
Cross Reference:
Gerontology 
Keywords: AMD, WAMD, Melatonin, retinal eye disease
 
Key Takeaway
Melatonin use is associated with a significant reduction in both the risk of developing AMD and the progression from nonexudative to exudative AMD, likely due to its antioxidant, anti-inflammatory, antiangiogenic, and mitochondrial-supportive effects.
Top

Originally published in JAMA Ophthalmology, 6 June 2024. This summary does not represent the original research, nor is it intended to replace the original research. Content Disclaimer
 

A recent study published in JAMA Ophthalmology on June 6, 2024, suggests that melatonin supplementation could significantly reduce the risk of developing age-related macular degeneration (AMD) and slow its progression.

In the retrospective cohort study, researchers analysed electronic medical records from the TriNetX database. They included patients aged 50 years or older from two groups: those without a history of AMD (AMD-naive group) and those with nonexudative AMD (nonexudative AMD group). The patients were then grouped based on their use of melatonin or lack thereof (control group).

The researchers employed Propensity Score Matching (PSM) to match patients in both groups based on variables such as age, medical history, and use of non-melatonin sleep medications.

The study evaluated the risk ratios and confidence intervals ( 95% CIs) to compare outcomes between the melatonin and control groups. In the AMD-naive group, they assessed new diagnoses of any AMD, while in the nonexudative AMD group, the focus was on progression to exudative AMD.

Key findings from the study include:
In the 21,523 patients with no history of AMD, melatonin use was associated with a 58% reduction in the risk of developing AMD.
• Of the 66,253 patients with preexisting nonexudative AMD, melatonin supplementation was linked to a 56% lower risk of progression to exudative AMD.


The authors attribute these potential benefits to melatonin’s antioxidant and anti-inflammatory properties. Additionally, melatonin may have antiangiogenic effects and help maintain mitochondrial function, which are critical in preventing the development and progression of AMD.

Previous research in both animal and human studies has supported these beneficial properties, suggesting melatonin as a promising therapeutic option in AMD management.

 

Access the original article
 

Jeong H, Shaia JK, Markle JC, Talcott KE, Singh RP. Melatonin and Risk of Age-Related Macular Degeneration. JAMA Ophthalmol. Published online June 06, 2024. doi:10.1001/jamaophthalmol.2024.1822

 


 Back to top


Disclaimer
This article is compiled from a variety of resources researched and compiled by the contributor. It is in no way presented as an original work.  Every effort has been made to attribute quotes and content correctly. Where possible, all information has been independently verified. The Medical Education Network bears no responsibility for any inaccuracies which may occur from the use of third-party sources. If you have any queries regarding this article contact us 


Fact-checking Policy
The Medical Education Network makes every effort to review and fact-check the articles used as source material in our summaries and original material. We have strict guidelines in relation to the publications we use as our source data, favouring peer-reviewed research wherever possible. Every effort is made to ensure that the information contained here is an accurate reflection of the original material. Should you find inaccuracies, out of date content or have any additional issues with our articles, please make use of the contact us form to notify us.

Rapid SSL

The Medical Education Network
Powered by eLecture, a VisualLive Solution